Baker IDI exists to reduce death and disability from cardiovascular disease and diabetes. To do this successfully Baker IDI needs to ensure that laboratory findings are translated into benefits for patients. The commercialisation of research activities is one of the most effective ways of ensuring that knowledge and ideas developed by our scientists improve the lives of people living with, and at risk of, cardiovascular disease and diabetes.
A hierarchy of principles informs the way Baker IDI enters into technology transfer initiatives and these are considered in every commercialisation venture. They include:
-
Seeing the generation of new ideas applied and taken up in the commercial world in a way which ensures they are used to improve health
-
The mitigation of risk associated with commercialisation pursuits
-
The attraction of funding to support basic research and development at Baker IDI
-
Profit from the commercialisation of technology developed at Baker IDI directly returned to support future research
-
Providing an appropriate level of personal reward and incentive to individual researchers involved in the development of new technologies.
The commercial partnerships we develop provide us with an opportunity to interact with scientists and research in the commercial sector. This is one useful indicator of the currency of our own research, and an important source of funding for our research activity.